Pachner AR - Search Results

1

Neutralizing antibodies to biological therapies: A "touch of gray" vs a "black and white" story.

Freedman MS, Pachner AR. Freedman MS, et al. Among authors: pachner ar. Neurology. 2007 Oct 2;69(14):1386-7. doi: 10.1212/01.wnl.0000282011.92098.68. Neurology. 2007. PMID: 17909150 No abstract available.

2

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators. Pachner AR, et al. Neurology. 2009 Nov 3;73(18):1493-500. doi: 10.1212/WNL.0b013e3181bf98db. Neurology. 2009. PMID: 19884577 Clinical Trial.

3

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.

4

Anti-interferon antibodies: surprises and lessons.

Pachner A. Pachner A. Lancet Neurol. 2004 Sep;3(9):515. doi: 10.1016/S1474-4422(04)00847-6. Lancet Neurol. 2004. PMID: 15324716 No abstract available.

5

Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Pachner AR. Pachner AR. Neurology. 2007 Oct 9;69(15):1555; author reply 1565. doi: 10.1212/01.wnl.0000295672.17358.95. Neurology. 2007. PMID: 17923620 No abstract available.

6

Interferon beta treatment of multiple sclerosis.

Pachner AR. Pachner AR. Neurology. 1994 Jan;44(1):188; author reply 188-90. doi: 10.1212/wnl.44.1.188. Neurology. 1994. PMID: 8290075 No abstract available.

7

MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.

Pachner A, Narayan K, Price N, Hurd M, Dail D. Pachner A, et al. Mol Diagn. 2003;7(1):17-25. doi: 10.1007/BF03260016. Mol Diagn. 2003. PMID: 14529316

8

Neutralizing anti-IFNbeta antibodies: clarity and confusion.

Pachner AR. Pachner AR. Mult Scler. 2007 Nov;13(9):1081-2. doi: 10.1177/1352458507082093. Mult Scler. 2007. PMID: 17967835 No abstract available.

9

Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans.

Fernald GH, Knott S, Pachner A, Caillier SJ, Narayan K, Oksenberg JR, Mousavi P, Baranzini SE. Fernald GH, et al. J Immunol. 2007 Apr 15;178(8):5076-85. doi: 10.4049/jimmunol.178.8.5076. J Immunol. 2007. PMID: 17404290

10

Neuropathy and IgM paraproteinemia: differential binding of IgM M-proteins to peripheral nerve glycolipids.

Kusunoki S, Kohriyama T, Pachner AR, Latov N, Yu RK. Kusunoki S, et al. Among authors: pachner ar. Neurology. 1987 Nov;37(11):1795-7. doi: 10.1212/wnl.37.11.1795. Neurology. 1987. PMID: 2823182

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters